about
Nicotinic receptor-mediated effects on appetite and food intakeObesity pharmacotherapy: current perspectives and future directionsHypersensitization of the Orexin 1 receptor by the CB1 receptor: evidence for cross-talk blocked by the specific CB1 antagonist, SR141716Enteropeptidase: a gene associated with a starvation human phenotype and a novel target for obesity treatmentThe role of ATF-2 family transcription factors in adipocyte differentiation: antiobesity effects of p38 inhibitorsCB1 cannabinoid receptor-mediated modulation of food intake in mice.Panniculectomy--an option for people who are morbidly obese.Contemporary approaches into obesity: drugs and genes.New aspects of melanocortin signaling: a role for PRCP in α-MSH degradationProlyl carboxypeptidase and its inhibitors in metabolism.Alpha-melanocyte stimulating hormone: production and degradation.Comprehensive review on herbal medicine for energy intake suppression.Overview of microarrays in drug discovery and development.Plant-derived food ingredients for stimulation of energy expenditure.The sustainability of interactions between the orexin-1 receptor and beta-arrestin-2 is defined by a single C-terminal cluster of hydroxy amino acids and modulates the kinetics of ERK MAPK regulation.5-Hydroxytryptamine Receptor Subtypes and their Modulators with Therapeutic Potentials.Widdrol-induced lipolysis is mediated by PKC and MEK/ERK in 3T3-L1 adipocytes.Food intake is inhibited by oral oleoylethanolamide.Plantago maxima leaves extract inhibits adipogenic action of a high-fat diet in female Wistar rats.Identification of bioactive metabolites against adenosine A1 receptor using NMR-based metabolomics
P2860
Q24646751-ED86C8BF-4757-4198-9FD4-44C9E6CC12CFQ26828559-F492B1E8-CC36-41F2-B1B3-A3083961F449Q28190374-0435E5C4-1FAF-4C2E-BEF0-EDA3083F1B28Q28485316-C0CFC0BB-9083-4E19-B6D0-FE46781301BCQ28513382-DD76129F-3E8A-475A-BBD9-AD1EBDB35F14Q35048878-D896FE8A-5CE5-4D1C-9BCB-7A556CB76781Q35111264-A8923A2F-5F51-480B-8374-27EF69533FE3Q35992004-5D0E8BD4-6F3F-43B6-A477-FD8C85EC5478Q36616975-12D96C19-CCC8-4FD9-B8D6-1C5B83BE675FQ37483430-84AD0CDD-2DAD-45E3-B5D7-692BED144F77Q37771277-324E728F-D20E-4BD3-914D-1D4BA03F72F6Q37775716-CB760721-4C34-46A6-9368-07F2766031D8Q37940364-B758FE1F-CBF0-4AD8-9951-ABB23CA98B7EQ38159762-1FB79433-373E-453C-95E0-81AE58C0CD5DQ40463546-18C1DD1A-F673-4380-8ED3-19CA5A1C9066Q41980535-94567679-B43F-49EF-85AD-692CFFA6B293Q42823090-6CB436EA-5729-40DD-9B2E-2B8D8CB4CF66Q44827114-DF3890CF-A29B-4EA0-9AAE-CBEB3238ED51Q51199176-34984476-7044-477A-8A16-BB19D02BC434Q57057864-42A0CC43-BABE-4ABA-A517-7037BF03CE21
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Pharmacotherapy of obesity: targets and perspectives.
@ast
Pharmacotherapy of obesity: targets and perspectives.
@en
Pharmacotherapy of obesity: targets and perspectives.
@nl
type
label
Pharmacotherapy of obesity: targets and perspectives.
@ast
Pharmacotherapy of obesity: targets and perspectives.
@en
Pharmacotherapy of obesity: targets and perspectives.
@nl
prefLabel
Pharmacotherapy of obesity: targets and perspectives.
@ast
Pharmacotherapy of obesity: targets and perspectives.
@en
Pharmacotherapy of obesity: targets and perspectives.
@nl
P2093
P1476
Pharmacotherapy of obesity: targets and perspectives.
@en
P2093
P304
P356
10.1016/S0165-6147(00)01664-3
P577
2001-05-01T00:00:00Z